丹诺医药-B今日盘中大涨5.94%，引起了市场的广泛关注。
消息面上，公司公开发售阶段获得9015.11倍的超额认购，成为今年港股主板超购倍数第二高的新股，显示出市场对其的强烈兴趣。更重要的是，公司的核心产品利福特尼唑是全球首个针对幽门螺杆菌感染的新分子实体候选药物，已于去年8月向国家药监局提交新药上市申请，预计今年底获批。中国幽门螺杆菌感染率约44%，涉及超6亿患者，市场空间极为广阔。
此外，公司的另一核心产品利福喹酮注射剂正在推进全球III期临床试验，这是目前唯一处于后期临床开发阶段的人工关节感染小分子候选药物。这些积极进展共同增强了投资者对公司未来发展的信心，推动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.